A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Clinical trial NCT05562882 · UNKNOWN

Trial details

NCT number: NCT05562882
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia

Start date: 2022-12-10
Primary completion: 2025-01-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.